Automated exposition of known and novel multiple myeloma genomic variants using a single sequencing platform

Patent metadata

Field	Value
Publication number	US-11141709-B2
Application number	US-201715804924-A
Country	US
Kind code	B2
Filing date	Nov 6, 2017
Priority date	Nov 4, 2016
Publication date	Oct 12, 2021
Grant date	Oct 12, 2021

Abstract

A sequencing capture array for identifying mutations in Multiple Myeloma is disclosed. Also disclosed are targeted next generation sequencing methods for identifying SNV, CNV, and translocation mutations in Multiple Myeloma tumor cells. A capture array representing fewer than 500 genes implicated in Multiple Myeloma can be used to analyze tumor mutations and create a personalized treatment plan for a Multiple Myeloma patient. Analytical methods are presented that allow tumor mutations to be elucidated with coverage at a sequencing depth of no more than 500×, or as low as 100×, with optimal efficiency achieved at a sequencing depth of about 300×.

First claim

What is claimed is:

1. A method of identifying multiple myeloma mutations in a subject in need thereof, comprising:
a) providing a DNA sequencing library comprising genomic DNA obtained from tumor cells of a subject;
b) providing a DNA sequencing library comprising genomic DNA obtained from non-tumor cells of the subject;
c) hybridizing the sequencing library comprising the genomic DNA obtained from the tumor to a set of biotinylated oligonucleotide probes, wherein each biotinylated oligonucleotide probe specifically hybridizes to:
i) a gene of at least 400 genes selected from the following 465 genes: DTNB, DNMT3A, ULK4, TRAK1, DNAH11, CDCA7L, FGFR3, WHSC1, CCND3, CCND1, MAF, MAFB, CKS1B, ANP32E, LTBR, MAP4K4, MYC, CDKN2C, RBI, CDKN2A, NRAS, KRAS, BRAF, PIK3CA, AKT1, TRAF3, CYLD, DKKI, FRZB, DNAH5, XBP1P1, PRDM1, IRF4, TP53, MRE11A, PARP1, DIS3, FAM46C, LRRK2, KDM6A, MLL, HOXA9, KDM6B, FAF1, BIRC2, BIRC3, WWOX, ACTG1, FNDC3A, MAX, TNKS, RPL10, BCL7A, EGR1, SP140, GCET2, HIST1H3G, SNRNP48, BAGE2, MEOX1, FERMT2, PRND, TRIP12, DNAH2, RASA2, PLA2G2D, COBLL1, ATF71P, GSTO2, SLC24A1, AASS, RBM25, ROBO2, THRAP3, ZNF326, GNG7, IF144, STARD13, HAUS3, TTC7B, CDKN1B, RNF151, SLC36A1, FAM153B, ORIL8, PRUNE2, COL4A1, USP50, SAMHD1, CXCR4, CHD2, KRTDAP, PTCH2, FBXO36, ABCC4, UBB, YTHDF2, HUWE1, NLRC5, CDH8, PHOX2B, CDCA2, MOGAT3, PSMD1, EXOG, GRIA2, CCDC144NL, IQSEC1, CKM, SYMPK, DAAM1, PTPRZ1, ORIN2, AGTR2, DUSP28, ADCY8, ACACA, PRIM2, DOLK, CST4, ACSM4, TMCO3, HTR6, OR1S2, NDUFAF3, FAM122C, SLC48A1, HIST1H3H, PNRC1I, NALCN, COL11A2, LCE3A, ZNF431, HERC4, TMEM143, CDC27, FXYD6, OR5P3, MALL, PLXDC2, EGFL6, CELSR2, PHKB, IRX2, PRKD2, STX5, TOM1LI, COX7B2, RNF40, PTPRD, MMP7, YAP1, MSRA, KIAA1377, SOX7, FAM167A, RP1LI, XKR6, CSMD2, PDE4DIP, FLG, HMCN1, RGS2, USH2A, OBSCN, RYR2, ANK3, TACC2, MK167, LRRC4C, FAT3, DYNC2H1, BTG1, EP400, AHNAK2, RYR3, HYDIN, ZFBX3, DNAH9, LAMA1, ZNF208, ZNF257, RYR1, FCGBP, NRXN1, NEB, SCN2A, FRG1B, BSN, ROBO1, KALRN, ANK2, FAT4, TRIO, FAM134B, MYO10, CMYA5, VCAN, FBN2, PKHD1, DST, SYNE1, HECW1, PCLO, PCMTD1, ZFHX4, CSMD3, MLLT3, TRPM3, GJB3, KTI12, DIRAS3, HIST2H3D, HIST2H2BE, HIST2H2AC, HIST3H2A, NAMPTL, RBMXL2, CDC42EP2, KRTAP5-10, FUT4, HIST4H4, ATXN7L3B, PABPC3, SPRY2, GREM1, EID1, IMP3, SOCS1, NACA2, TRAPPC5, RPS28, ZNF493, RPSAP58, FFAR2, EID2B, FAM84A, FOXD4LI, TMEM177, KCNE4, MOV10LI, LRRC3B, RPP14, CGGBP1, H1FX, SLC35G2, CRIPAK, DCAF16, PURA, HIST1H4B, HIST1H2BB, HIST1H3C, HIST1H1C, HIST1H4C, HIST1H2AC, HIST1H1E, HIST1H3E, HIST1H3D, HIST1H2BF, HIST1H4E, HIST1H2AE, HIST1H1D, HIST1H3F, HIST1H4H, HIST1H2BJ, HIST1H2AG, HIST1H2BK, HIST1H2BL, HIST1H2BM, HIST1H2AM, HIST1H2BO, LTB, C2, TBCC, TPBG, CLDN4, PEG10, RNF133, NATI, AQP7, GCNT1, DIRAS2, TMSB4X, CPXCR1, RPA4, TCEAL3, MAGEC3, NOTCH2, EHD1, AKAP6, LRRTM4, VCPIP1, ABCA2, LYPLA2, DTX1, MYOM1, TGFB1, RRBP1, RPRD1B, IGLL5, ZNF148, RNF150, ATM, ARID2, SCAF11, WDR87, SETD2, EXOC4, MAGED1, SLIT3, SLC6A11, ZNF319, ZNF100, ZNF91, ZNF681, ZNF235, ZNF616, ZNF721, KCNH4, GRM7, TJP3, FMN1, TLR5, VDR, ADRA2B, LRRN1, SLIT2, ATR, AICDA, SUPT5H, UNG, CCDC88A, MSH2, NLRP2, PAX5, TCF3, ID2, NFKB1, NFKB2, RELA, PRKACB, PTBP2, APEX1, APEX2, MSH6, TRJM28, SUPT6H, MSH3, MSH5, POLQ, RNF8, RNF168, REV3L, PMS2, PAXIP1, PCNA, MLH1, MLH3, EXO1, XRCC6, XRCC5, LIG4, XRCC4, PRKDC, DCLRE1C, NHEJ1, NBN, RAD50, RBBP8, LIG3, LIG1, XRCC1, BBC3, BCL2L11, PRKCD, BCL2L1, TNFSF13B, RAG1, RAG2, H2AFX, MDC1, TP53BP1, CHEK2, BLM, R1F1, SAMSN1, LILRB3, U2AF1, SF3B1, SRSF2, NADK, DNAJC11, DENND4B, KCNN3, ARHGEF11, CR1, KIF26B, AGAP5, TMEM216, TECTA, ZCRB1, CLIP1, UPF3A, SYNRG, PNKP, 1DH1, RALGAPA2, NCOA6, CTCFL, EFCAB6, TOMM70A, INTS12, ANKHD1, ZNF318, PLG, TBP, CNTNAP2, ANKRD18B, PCSK5, SHC3, DDX11, HLA-A, HLA-DRB1, ISPD, ALK, ANTXR2, ARID1A, AXL, BA12, BCORL1, BRCA2, CARD11, CCDC155, CDHR1, CHD3, CNKSR2, DCLK2, DICER1, HOXA4, IFG1R, IKBKB, IL6ST, JAK2, KIT, MED12, MED12L, MERTK, MLL5, MTOR, NBEA, NOTCH1, PIK3C2G, PIM1, PTPN11, PTPN14, ROS1, SKP2, SPOP, ST7, STAT3, TP63, TPTE, XBP1, ZIM3, and ZNF717; or
ii) a sequence from a set of sequences tiled in an unbiased fashion from ˜50 Kb upstream to ˜50 Kb downstream of the IGH locus;

d) sequencing the library comprising the genomic DNA obtained from the tumor cells hybridized to the biotinylated oligonucleotide probes to a maximum average depth of 500×;
e) hybridizing the sequencing library comprising the genomic DNA obtained from the non-tumor cells to the biotinylated oligonucleotide probes;
f) sequencing the library comprising the genomic DNA obtained from the non-tumor cells hybridized to the biotinylated oligonucleotide probes to a maximum average depth of 500×; and
g) identifying variants in the genomic DNA obtained from the tumor cells compared to the genomic DNA obtained from the non-tumor cells, thereby identifying individual genetic mutations in multiple myeloma in the subject.

2. A method in accordance with claim 1 , wherein the at least 400 genes consist of 465 genes which are altered in multiple myeloma.

3. A method in accordance with claim 1 wherein the biotinylated oligonucleotide probes which are tiled in an unbiased fashion from ˜50 Kb upstream to ˜50 Kb downstream of the IGH locus include biotinylated oligonucleotide probes within the variable (IGHV), diversity (IGHD), joining (IGHJ), and constant/switch regions.

4. A method in accordance with claim 1 , wherein the biotinylated oligonucleotide probes comprise probes that hybridize to NRAS, KRAS, FAM46C, TP53, D1S3, IGLL5 and BRAF.

5. A method in accordance with claim 1 , wherein the biotinylated oligonucleotide probes comprise probes that hybridize to ATM, BRCA2, CARD11, CCND1, CCND3, CYLD, DIS3, DNAH5, DNAH11, DNMT3A, FAM46C, FGFR3, JAK2, KDM6A, KDM6B, KIT, KRAS, MAF, MAFB, MTOR, MYC, NFKB1, NOTCH1, NOTCH2, PARP1, RB1, TRAF3, and WHSC1.

6. A method in accordance with claim 1 , wherein the biotinylated oligonucleotide probes comprise probes that hybridize to CLIP1, CSMD3, EP400, FMN1, FRG1B, KDM6A, KRAS, LAMA1, MLLT3, MSH2, MSH6, NOTCH1, OR1S2, PAX5, and RB1.

7. A method of identifying multiple myeloma mutations in a subject in need thereof, comprising:
a) providing a DNA sequencing library comprising genomic DNA obtained from tumor cells of a subject;
b) providing a DNA sequencing library comprising genomic DNA obtained from non-tumor cells of the subject;
c) hybridizing the sequencing library comprising the genomic DNA obtained from the tumor to a set of biotinylated oligonucleotide probes, wherein each biotinylated oligonucleotide probe specifically hybridizes to:
i) a gene of at least 400 genes selected from the following 465 genes: DTNB, DNMT3A, ULK4, TRAK1, DNAH11, CDCA7L, FGFR3, WHSC1, CCND3, CCND1, MAF, MAFB, CKS1B, ANP32E, LTBR, MAP4K4, MYC, CDKN2C, RBI, CDKN2A, NRAS, KRAS, BRAF, PIK3CA, AKT1, TRAF3, CYLD, DKKI, FRZB, DNAH5, XBP1P1, PRDM1, IRF4, TP53, MRE11A, PARP1, DIS3, FAM46C, LRRK2, KDM6A, MLL, HOXA9, KDM6B, FAF1, BIRC2, BIRC3, WWOX, ACTG1, FNDC3A, MAX, TNKS, RPL10, BCL7A, EGR1, SP140, GCET2, HIST1H3G, SNRNP48, BAGE2, MEOX1, FERMT2, PRND, TRIP12, DNAH2, RASA2, PLA2G2D, COBLL1, ATF71P, GSTO2, SLC24A1, AASS, RBM25, ROBO2, THRAP3, ZNF326, GNG7, IF144, STARD13, HAUS3, TTC7B, CDKN1B, RNF151, SLC36A1, FAM153B, OR1L8, PRUNE2, COL4A1, USP50, SAMHD1, CXCR4, CHD2, KRTDAP, PTCH2, FBXO36, ABCC4, UBB, YTHDF2, HUWE1, NLRCS, CDH8, PHOX2B, CDCA2, MOGAT3, PSMD1, EXOG, GRIA2, CCDC144NL, IQSEC1, CKM, SYMPK, DAAM1, PTPRZ1, OR1N2, AGTR2, DUSP28, ADCY8, ACACA, PRIM2, DOLK, CST4, ACSM4, TMCO3, HTR6, OR1S2, NDUFAF3, FAM122C, SLC48A1, HIST1H3H, PNRC11, NALCN, COL11A2, LCE3A, ZNF431, HERC4, TMEM143, CDC27, FXYD6, OR5P3, MALL, PLXDC2, EGFL6, CELSR2, PHKB, IRX2, PRKD2, STXS, TOM1L1, COX7B2, RNF40, PTPRD, MMP7, YAP1, MSRA, K1AA1377, SOX7, FAM167A, RP1L1, XKR6, CSMD2, PDE4DIP, FLG, HMCN1, RGS2, USH2A, OBSCN, RYR2, ANK3, TACC2 , MK167, LRRC4C, FAT3, DYNC2H1, BTG1

Assignees

• Univ Washington
• Multiple Myeloma Res Foundation

Inventors

• White Brian
• Lanc Irena
• Fulton Robert
• Auclair Daniel
• Tomasson Michael H

Classifications

• G16B30/10 Primary

  Sequence alignment; Homology search · CPC title

• G16B20/10

  Ploidy or copy number detection · CPC title

• G16B20/40

  Population genetics; Linkage disequilibrium · CPC title

• G16B30/00

  ICT specially adapted for sequence analysis involving nucleotides or amino acids · CPC title

• B01J2219/00387

  Applications using probes · CPC title